Form4insider filings, from the source

SEC Form 4 · accession 0001209191-18-020859

TEVA PHARMACEUTICAL INDUSTRIES LTD · TEVA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner
Hafrun Fridriksdottir
Officer — Executive VP, Global R&D
Period of report
Mar 17, 2018
Accepted (ET)
Mar 20, 2018 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000818686

Table I — non-derivative securities

SecurityDateCodeSharesPriceA/DOwned afterD/INature of ownership
Ordinary SharesF1,F2Mar 17, 2018M747—A7,134D
Ordinary SharesF1,F2Mar 17, 2018M265—A7,399D
Ordinary SharesF1,F4Mar 19, 2018S257$17.878D7,142D
Ordinary SharesF1,F4Mar 19, 2018S91$17.878D7,051D

Table II — derivative securities

SecurityConv. / exercise priceDateCodeSharesA/DExercisableExpiresUnderlyingUnderlying sharesOwned afterD/I
Restricted Share UnitsF2,F5,F1—Mar 17, 2018M747D——Ordinary Shares7471,495D
Restricted Share UnitsF2,F6,F1—Mar 17, 2018M265D——Ordinary Shares265531D

Explanation of responses